PWE-058 Outcomes of using therapeutic drug monitoring to guide switching from originator infliximab to biosimilar infliximab

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

There is evidence that biosimilar infliximab (BSI) has comparable efficacy and safety to originator infliximab (OI) and is significantly cheaper.

Introduction

ECCO guidelines suggest therapeutic drug monitoring (TDM) can help determine whether infliximab (IFX) should be continued or dose-adjusted during maintenance treatment of inflammatory bowel disease (IBD).

Method

Our unit developed a switch programme in order to take advantage of the cost savings associated with BSI.

Method

We identified patients established on OI as IBD maintenance therapy (n=76). Our IBD nurses counselled patients, gained their consent to switch from OI to BSI, and obtained IFX TDM samples. We audited the usefulness of IFX TDM and whether concomitant immunomodulation (IM) or pretreatment with hydrocortisone were associated with lower rates of antibodies to infliximab (ATI).

Results

3 patients were excluded as their trough levels of IFX (TLI) were felt inaccurate due to the timing of the test. 73 were included: 16 (21.9%) had therapeutic TLI (3–7 µg/mL), 3 (4.12%) had high TLI (>7 µg/mL), 37 (50.68%) had low TLI (0.8–2.9 µg/ml) and 17 (23.3%) had TLI <0.8 µg/ml of whom 15 had ATI and 2 did not.

Results

IFX TDM changed management in 46 (63%) patients: IFX was dose-optimised in 24 (32.9%) patients and discontinued in 14 (19.2%) others (7 were started on adalimumab or vedolizumab, and 7 stopped biological therapy altogether). 8 (10.9%) patients were re-staged with a view to stopping IFX.

Results

No changes were made in 27 (37%) patients: 16 (21.9%) had optimal TLI, 4 (5.5%) were in remission with only marginally suboptimal TLI and no ATI, and 7 (9.6%) had not yet had their IFX TDM reviewed by the MDT.

Results

Only one patient did not consent to switching from OI to BSI. 93.5% of patients continuing on IFX were switched from OI to BSI.

Results

All patients received some form of co-treatment in an attempt to reduce the development of ATI (table 1). Despite this, 41 (53.9%) patients had ATI. The mean duration of IFX therapy was 34.3 months overall, 33 months in those with ATI, and 35.8 months in those without ATI.

Conclusion

A switch programme facilitates cost savings, and is acceptable to patients if the rationale is properly explained.

Conclusion

IFX TDM altered management in 63% of our patients and therefore should be incorporated in switch programmes.

Conclusion

More than half of patients had ATI. This may be explained by the fact that patients had been on IFX for a prolonged time. In our cohort it appears that concomitant IM was better at preventing ATI than pretreatment with hydrocortisone.

Disclosure of Interest

None Declared

Related Topics

    loading  Loading Related Articles